Anatara Lifesciences (ASX:ANR) Shares Buyback Ratio %: -0.75 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Anatara Lifesciences Shares Buyback Ratio %?

Anatara Lifesciences ASX:ANR Shares Buyback Ratio % is -0.75 as of Sep. 22, 2026. The stock has 5 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Anatara Lifesciences's current shares buyback ratio was -0.75%.

Anatara Lifesciences Shares Buyback Ratio % Related Terms

Anatara Lifesciences Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Anatara Lifesciences's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anatara Lifesciences Shares Buyback Ratio % Chart

Anatara Lifesciences Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.59 -62.81 -49.63 -11.64 -48.07

Anatara Lifesciences Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.85 -11.64 0.00 -46.96 -0.75

Anatara Lifesciences Shares Buyback Ratio % Calculation

Anatara Lifesciences's Shares Buyback Ratio for the fiscal year that ended in Jun. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2025 ) - Shares Outstanding (EOP) (A: Jun. 2026 )) / Shares Outstanding (EOP) (A: Jun. 2025 )
=(213.383727 - 315.950765) / 213.383727
=-48.07%

Anatara Lifesciences's Shares Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2025 ) - Shares Outstanding (EOP) (A: Jun. 2026 )) / Shares Outstanding (EOP) (A: Dec. 2025 )
=(313.590339 - 315.950765) / 313.590339
=-0.75%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -0.75 mean?
Anatara Lifesciences (ASX:ANR) has a Shares Buyback Ratio % of -0.75 as of Sep. 22, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Anatara Lifesciences and its competitors.
Is Anatara Lifesciences' Shares Buyback Ratio % too high?
Anatara Lifesciences' current Shares Buyback Ratio % is -0.75.
How does Anatara Lifesciences' Shares Buyback Ratio % compare to VRTX and REGN?
Anatara Lifesciences' Shares Buyback Ratio % of -0.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Anatara Lifesciences and its competitors. Anatara Lifesciences's current Shares Buyback Ratio % is -0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anatara Lifesciences stock overvalued right now?
Anatara Lifesciences (ASX:ANR) has a current Shares Buyback Ratio % of -0.75. The current Shares Buyback Ratio % is -0.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Anatara Lifesciences (ASX:ANR), the current Shares Buyback Ratio % is -0.75 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anatara Lifesciences Business Description

Address c/- Perks, 81 Flinders Street, Level 8, Adelaide, SA, AUS, 5000
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.